chemiluminescent method northern lights nl-mercodia (Mercodia Inc)
90
Structured Review
Mercodia Inc
chemiluminescent method northern lights nl-mercodia
Chemiluminescent Method Northern Lights Nl Mercodia, supplied by Mercodia Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nls+method/chemiluminescent+method+northern+lights+nl+mercodia/pm32524277-40-8-10
Average 90 stars, based on 1 article reviews
Chemiluminescent Method Northern Lights Nl Mercodia, supplied by Mercodia Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/nls+method/chemiluminescent+method+northern+lights+nl+mercodia/pm32524277-40-8-10
Average 90 stars, based on 1 article reviews
chemiluminescent method northern lights nl-mercodia - by Bioz Stars,
2026-11
90/100 stars
Images
Related Articles
Northern Blot:Article Title: Is pasireotide-induced diabetes mellitus predictable? A pilot study on the effect of a single dose of pasireotide on glucose homeostasis. Article Snippet: Introduction Pasireotide (PAS) is an effective treatment for Cushing’s disease (CD) but its use is burdened by an associated high incidence of diabetes mellitus (DM).. The aim of this study was to examine the effect of a single subcutaneous injection of PAS on glucose metabolism in CD, and to identify predictors of DM onset.. Methods Fifteen patients with CD (13 females, 2 males; median age 43 years [IQR 34–50]) were submitted to an acute PAS test (600 μg s.c.), measuring glucose, insulin, C-peptide, GIP, glucagon, GLP-1, ACTH, and cortisol at the baseline and every 30 min for 2 h. Then they were treated twice daily with PAS 600 μg, and followed up with clinical and hormone assessments for a median of 6 months [2–13]. Clinical Proteomics:Article Title: Is pasireotide-induced diabetes mellitus predictable? A pilot study on the effect of a single dose of pasireotide on glucose homeostasis. Article Snippet: Introduction Pasireotide (PAS) is an effective treatment for Cushing’s disease (CD) but its use is burdened by an associated high incidence of diabetes mellitus (DM).. The aim of this study was to examine the effect of a single subcutaneous injection of PAS on glucose metabolism in CD, and to identify predictors of DM onset.. Methods Fifteen patients with CD (13 females, 2 males; median age 43 years [IQR 34–50]) were submitted to an acute PAS test (600 μg s.c.), measuring glucose, insulin, C-peptide, GIP, glucagon, GLP-1, ACTH, and cortisol at the baseline and every 30 min for 2 h. Then they were treated twice daily with PAS 600 μg, and followed up with clinical and hormone assessments for a median of 6 months [2–13]. Enzyme-linked Immunosorbent Assay:Article Title: Is pasireotide-induced diabetes mellitus predictable? A pilot study on the effect of a single dose of pasireotide on glucose homeostasis. Article Snippet: Introduction Pasireotide (PAS) is an effective treatment for Cushing’s disease (CD) but its use is burdened by an associated high incidence of diabetes mellitus (DM).. The aim of this study was to examine the effect of a single subcutaneous injection of PAS on glucose metabolism in CD, and to identify predictors of DM onset.. Methods Fifteen patients with CD (13 females, 2 males; median age 43 years [IQR 34–50]) were submitted to an acute PAS test (600 μg s.c.), measuring glucose, insulin, C-peptide, GIP, glucagon, GLP-1, ACTH, and cortisol at the baseline and every 30 min for 2 h. Then they were treated twice daily with PAS 600 μg, and followed up with clinical and hormone assessments for a median of 6 months [2–13]. Sandwich ELISA:Article Title: Is pasireotide-induced diabetes mellitus predictable? A pilot study on the effect of a single dose of pasireotide on glucose homeostasis. Article Snippet: Introduction Pasireotide (PAS) is an effective treatment for Cushing’s disease (CD) but its use is burdened by an associated high incidence of diabetes mellitus (DM).. The aim of this study was to examine the effect of a single subcutaneous injection of PAS on glucose metabolism in CD, and to identify predictors of DM onset.. Methods Fifteen patients with CD (13 females, 2 males; median age 43 years [IQR 34–50]) were submitted to an acute PAS test (600 μg s.c.), measuring glucose, insulin, C-peptide, GIP, glucagon, GLP-1, ACTH, and cortisol at the baseline and every 30 min for 2 h. Then they were treated twice daily with PAS 600 μg, and followed up with clinical and hormone assessments for a median of 6 months [2–13]. |